Top

Published in:

Open Access 01-12-2017 | Review

The opioid epidemic: a central role for the blood brain barrier in opioid analgesia and abuse

Authors: Charles P. Schaefer, Margaret E. Tome, Thomas P. Davis

Published in: Fluids and Barriers of the CNS | Issue 1/2017

Abstract

Opioids are currently the primary treatment method used to manage both acute and chronic pain. In the past two to three decades, there has been a surge in the use, abuse and misuse of opioids. The mechanism by which opioids relieve pain and induce euphoria is dependent on the drug crossing the blood–brain barrier and accessing the central nervous system. This suggests the blood brain barrier plays a central role in both the benefits and risks of opioid use. The complex physiological responses to opioids that provide the benefits and drive the abuse also needs to be considered in the resolution of the opioid epidemic.

United States Department of Health and Human Services. The opioid epidemic: by the numbers. 2016;60. http://www.hhs.gov/sites/default/files/Factsheet-opioids-061516.pdf. Accessed 6 June 2016.

Rudd RA, Aleshire N, Zibbell JE, Gladden RM. Increases in drug and opioid overdose deaths—United States, 2000–2014. MMWR Morb Mortal Wkly Rep. 2016;64:1378–82.CrossRefPubMed

Joshi GP, Beck D, Emerson R, Halaszynki T, Jahr J, Lipman A, et al. Defining new directions for more effective management of surgical pain in the United States: highlights of the inaugural surgical pain congress ä. Highlights Inaug Surg Pain Congr. 2014;80:219–28.

Basbaum AI, Bautista DM, Scherrer G, Julius D. Cellular and molecular mechanisms of pain. Cell. 2009;139:267–84.CrossRefPubMedPubMedCentral

Woolf CJ, Ma Q. Nociceptors–noxious stimulus detectors. Neuron. 2007;55:353–64.CrossRefPubMed

Brownstein MJ. A brief history of opiates, opioid peptides, and opioid receptors. Proc Natl Acad Sci USA. 1993;90:5391–3.CrossRefPubMedPubMedCentral

Schiff PL. Opium and its alkaloids. Am J Pharm Educ. 2002;66:186–94.

Sertuner F. Trommsdorff’s J Pharm. 1806;47–93.

Wright CRA. On the action of organic acids and their anhydrides on the natural alkaloids. Part I. J Chem Soc. 1872;27:1031–43.

10.

Bockmuhl VM, Ehrhart G. Uber eine neue Klasse von spasmolytisch und aiialgetisch wirkenden Verbindungen. I. Eur J Org Chem. 1947;561:52–85.

11.

Fugelstad A, Stenbacka M, Leifman A, Nylander M, Thiblin I. Methadone maintenance treatment: the balance between life-saving treatment and fatal poisonings. Addiction. 2007;102:406–12.CrossRefPubMed

12.

Wilkerson RG, Kim HK, Windsor TA, Mareiniss DP. The opioid epidemic in the United States. Emerg Med Clin N Am. 2016;34:e1–23. https://doi.org/10.1016/j.emc.2015.11.002.CrossRef

13.

Porter J, Jick H. Addiction rare in patients treated with narcotics. N Engl J Med. 1980;302:123.PubMed

14.

Zenz M, Strumpf M, Tryba M. Long-term oral opioid therapy in patients with chronic nonmalignant pain. J Pain Symptom Manage. 1992;7:69–77.CrossRefPubMed

15.

Portenoy RK, Foley KM. Chronic use of opioid analgesics in non-malignant pain [letter]. Pain. 1987;29:257–62.CrossRef

16.

Weingarten MA. Chrnoic opioid therapy in patients with a remote history of substance abuse. J Pain Symptom Manage. 1991;6:2–3.CrossRefPubMed

17.

Okie S. A Flood of Opioids, a Rising Tide of Deaths. New England journal. N Engl J Med. 2010;363:1981–5. https://doi.org/10.1056/NEJMp1002530.CrossRefPubMed

18.

Cantrill SV, Brown MD, Carlisle RJ, Delaney KA, Hays DP, Nelson LS, et al. Clinical policy: critical issues in the prescribing of opioids for adult patients in the emergency department. Ann Emerg Med. 2012;60:499–525. https://doi.org/10.1016/j.annemergmed.2012.06.013.CrossRefPubMed

19.

Yaksh TL, Wallace MS. Chapter 18 : opioids, analgesia, and pain management. In: Goodman and Gilman’s: the pharmacological basis of therapeutics, 12th ed. New York: McGraw-Hill; 2011.

20.

Osbourne R, Joel S, Trew D, Slevin M. analgesic activity of morphine-6-glucuronide. Lancet. 1988;1:828.CrossRef

21.

Smith MT. Neuroexcitatory effects of morphine and hydromorphone: evidence implicating the 3-glucuronide metabolites. Clin Exp Pharmacol Physiol. 2000;27:524–8.CrossRefPubMed

22.

Sia AT, Lim Y, Lim ECP, Goh RWC, Law HY, Landau R, et al. A118G single nucleotide polymorphism of human mu-opioid receptor gene influences pain perception and patient-controlled intravenous morphine consumption after intrathecal morphine for postcesarean analgesia. Anesthesiology. 2008;109:520–6.CrossRefPubMed

23.

Yaksh TL. Pharmacology and mechanisms of opioid analgesic activity. Acta Anaesthesiol Scand. 1997;41(1 Pt 2):94–111.CrossRefPubMed

24.

Bundgaard M, Abbott NJ. All vertebrates started out with a glial blood–brain barrier 4–500 million years ago. Glia. 2008;56:699–708.CrossRefPubMed

25.

Mayer F, Mayer N, Chinn L, Pinsonneault RL, Bainton RJ. Evolutionary conservation of vertebrate blood–brain barrier chemoprotective mechanisms in Drosophila. J Neurosci. 2011;29:3538–50.CrossRef

26.

Mahringer A, Ott M, Fricker G. The blood brain barrier (BBB). Heidelberg: Springer; 2014. p. 1–20.

27.

Seleman M, Chapy H, Cisternino S, Courtin C, Smirnova M, Schlatter J, et al. Impact of P-glycoprotein at the blood–brain barrier on the uptake of heroin and its main metabolites: behavioral effects and consequences on the transcriptional responses and reinforcing properties. Psychopharmacology. 2014;231:3139–49.CrossRefPubMed

28.

Campbell AW. The blood–brain barrier. Altern Ther. 2016;22:6–7.

29.

Nakagawa S, Deli MA, Kawaguchi H, Shimizudani T, Shimono T, Kittel Á, et al. A new blood–brain barrier model using primary rat brain endothelial cells, pericytes and astrocytes. Neurochem Int. 2009;54:253–63.CrossRefPubMed

30.

Abbott NJ, Patabendige AAK, Dolman DEM, Yusof SR, Begley DJ. Structure and function of the blood–brain barrier. Neurobiol Dis. 2010;37:13–25.CrossRefPubMed

31.

Dick AP, Harik SI, Klip A, Walker DM. Identification and characterization of the glucose transporter of the blood–brain barrier by cytochalasin B binding and immunological reactivity. Proc Natl Acad Sci USA. 1984;81:7233–7.CrossRefPubMedPubMedCentral

32.

Jones PM, George AM. The ABC transporter structure and mechanism: perspectives on recent research. Cell Mol Life Sci. 2004;61:682–99.CrossRefPubMed

33.

Cordon-Cardo C, O’Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood–brain barrier sites. Proc Natl Acad Sci USA. 1989;86:695–8.CrossRefPubMedPubMedCentral

34.

Schinkel AH, Smit JJM, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood–brain barrier and to increased sensitivity to drugs. Cell. 1994;77:491–502.CrossRefPubMed

35.

Bostrom E, Hammarlund-Udenaes M, Simonsson US. Blood–brain barrier transport helps to explain discrepancies in in vivo potency between oxycodone and morphine. Anesthesiology. 2008;108:495–505. https://doi.org/10.1097/ALN.0b013e318164cf9e.CrossRefPubMed

36.

Ambudkar SV, Kim I, Sauna ZE. The power of the pump: mechanisms of action of P-glycoprotein (ABCB1). Eur J Pharm Sci. 2006;27:392–400.CrossRefPubMed

37.

Thomas H, Coley H. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control. 2003;10:159–65.CrossRefPubMed

38.

Liang X, Aszalos A. Multidrug transporters as drug targets. Curr Drug Targets. 2006;7:911–21.CrossRefPubMed

39.

Yamada H, Ishii K, Ishii Y, Ieiri I, Nishio S, Morioka T, et al. Formation of highly analgesic morphine-6-glucuronide following physiologic concentration of morphine in human brain. J Toxicol Sci. 2003;28:395–401.CrossRefPubMed

40.

Tournier N, Chevillard L, Megarbane B, Scherrmann J, Pirnay S, Decleves X. Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2). Int J Neurophychopharmacology. 2010;13:905–15.CrossRef

41.

Fujita KI, Ando Y, Yamamoto W, Miya T, Endo H, Sunakawa Y, et al. Association of UGT2B7 and ABCB1 genotypes with morphine-induced adverse drug reactions in Japanese patients with cancer. Cancer Chemother Pharmacol. 2010;65:251–8.CrossRefPubMed

42.

De Gregori S, De Gregori M, Ranzani GN, Allegri M, Minella C, Regazzi M. Morphine metabolism, transport and brain disposition. Metab Brain Dis. 2012;27:1–5.CrossRefPubMed

43.

Bourasset F, Cisternino S, Temsamani J, Scherrmann J. Evidence for an active transport of morphine-6-β-d-glucuronide but not P-glycoprotein-mediated at the blood–brain barrier. J Neurochem. 2003;86:1564–7.CrossRefPubMed

44.

Balayssac D, Cayre A, Ling B, Maublant J, Penault-Llorca F, Eschalier A, et al. Increase in morphine antinociceptive activity by a P-glycoprotein inhibitor in cisplatin-induced neuropathy. Neurosci Lett. 2009;465:108–12.CrossRefPubMed

45.

Zelcer N, van de Wetering K, Hillebrand M, Sarton E, Kuil A, Wielinga PR, et al. Mice lacking multidrug resistance protein 3 show altered morphine pharmacokinetics and morphine-6-glucuronide antinociception. Proc Natl Acad Sci USA. 2005;102:7274–9. https://doi.org/10.1073/pnas.0502530102.CrossRefPubMedPubMedCentral

46.

Wandel C, Kim R, Wood M, Ch MBB, Wood A, Ch MBB. Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein. Anesthesiology. 2002;86:913–20.CrossRef

47.

Montesinos RN, Moulari B, Gromand J, Beduneau A, Lamprecht A. Coadministration of P-glycoprotein modulators on loperamide pharmacokinetics and brain distribution. Drug Metab Dispos. 2014;42:700–6.CrossRefPubMed

48.

Regnard C, Twycross R, Mihalyo M, Wilcock A. Loperamide. J Pain Symptom Manag. 2011;42:319–23.CrossRef

49.

Schinkel AH, Wagenaar E, Mol CAAM, Van Deemter L. P-Glycoprotein in the blood–brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest. 1996;97:2517–24.CrossRefPubMedPubMedCentral

50.

Kaiko RF, Wallenstein SL, Rogers A. Relative analgesic potency of intramuscular heroin and morphine in cancer patients with postoperative pain and chronic pain due to cancer. NIDA Res Minigr Ser. 1981;34:213–9.

51.

Selley DE, Cao CC, Sexton T, Schwegel JA, Martin TJ, Childers SR. μ opioid receptor-mediated G-protein activation by heroin metabolites: evidence for greater efficacy of 6-monoacetylmorphine compared with morphine. Biochem Pharmacol. 2001;62:447–55.CrossRefPubMed

52.

Boix F, Andersen JM, Mørland J. Pharmacokinetic modeling of subcutaneous heroin and its metabolites in blood and brain of mice. Addict Biol. 2013;18:1–7.CrossRefPubMed

53.

Boström E, Simonsson USH, Hammarlund-Udenaes M. Oxycodone pharmacokinetics and pharmacodynamics in the rat in the presence of the P-glycoprotein inhibitor PSC833. J Pharm Sci. 2005;94:1060–6.CrossRefPubMed

54.

Silvasti M, Rosenburg P, Seppala T, Svartling N, Pitkanen M. Comparison of analgesic efficacy of oxycodone and morphine in postoperative intravenous patient-controlled analgesia. Acta Anaesthesiol Scand. 1998;42:576–80.CrossRefPubMed

55.

Bostrom E, Simonsson USH, Hamarlund-Udenases M. In vivo blood–brain barrier transport of oxycodone in the rat: indications for active influx and implications for pharmacokinetics/pharmacodynamics. Drug Metab Dispos. 2006;34:1624–31.CrossRefPubMed

56.

Okura T, Hattori A, Takano Y, Sato T, Hammarlund-udenaes M, Terasaki T, et al. Involvement of the pyrilamine transporter, a putative organic cation transporter, in blood–brain barrier transport of oxycodone. Drug Metab Dispos. 2008;36:2005–13.CrossRefPubMed

57.

Hagen NA, Wasylenko E. Methadone: outpatient titration and monitoring strategies in cancer patients. J Pain Symptom Manage. 1999;18:369–75.CrossRefPubMed

58.

Wang JS, Ruan Y, Taylor RM, Donovan JL, Markowitz JS, DeVane CL. Brain penetration of methadone (R)- and (S)-enantiomers is greatly increased by P-glycoprotein deficiency in the blood–brain barrier of Abcb1a gene knockout mice. Psychopharmacology. 2004;173:132–8.CrossRefPubMed

59.

Sullivan HR, Due SL. Urinary metabolites of dl-methadone in maintenance subjects. J Med Chem. 1973;16:909–13.CrossRefPubMed

60.

Mccance-katz EF. (R)-methadone versus racemic methadone: what is best for patient care? Addiction. 2011;106:687–8.CrossRefPubMedPubMedCentral

61.

Crettol S, Digon P, Powell Golay K, Brawand M, Eap CB. In vitro P-glycoprotein-mediated transport of (R)-, (S)-, (R,S)-methadone, LAAM and their main metabolites. Pharmacology. 2007;80:304–11.CrossRefPubMed

62.

Mercer SL, Coop A. Opioid analgesics and P-glycoprotein efflux transporters: a potential systems-level contribution to analgesic tolerance. Curr Top Med Chem. 2011;11:1157–64.CrossRefPubMedPubMedCentral

63.

Volpe DA, Mcmahon GA, Mellon RD, Katki AG, Parker RJ, Colatsky T, et al. Uniform assessment and ranking of opioid Mu receptor binding constants for selected opioid drugs. Regul Toxicol Pharmacol. 2011;59:385–90. https://doi.org/10.1016/j.yrtph.2010.12.007.CrossRefPubMed

64.

Henthorn TK, Liu Y, Mahapatro M, Ng K. Active transport of fentanyl by the blood–brain barrier 1. J Pharmacol Exp Ther. 1999;289:1084–9.PubMed

65.

Klepstad P, Dale O, Skorpen F, Borchgrevink PC, Kaasa S. Genetic variability and clinical efficacy of morphine. Acta Anaesthesiol Scand. 2005;49:902–8.CrossRefPubMed

66.

Xi Z, Stein EA. GABAergic mechanisms of opiate reinforcement. Alcohol Alcohol. 2002;37:485–94.CrossRefPubMed

67.

Doi K, Gibbons G. Improving postoperative pain management in orthopedic total joint surgical patients with opioid tolerance using the iowa model of evidence-based practice. ASPAN Natl Conf Abstr. 2014;29:e38.

68.

Pasternak GW. Molecular biology of opioid analgesia. J Pain Symptom Manage. 2005;29:2–9.CrossRef

69.

Yousif S, Saubamea B, Cisternino S, Marie-Claire C, Dauchy S, Scherrmann J-M, et al. Effect of chronic exposure to morphine on the rat blood–brain barrier: focus on the P-glycoprotein. J Neurochem. 2008;107:647–57.CrossRefPubMed

70.

Aquilante CL, Letrent SP, Pollack GM, Brouwer KL. Increased brain P-glycoprotein in morphine tolerant rats. Life Sci. 2000;66:L47–51.

71.

Li Y, Yue H, Xing Y, Sun H, Pan Z, Xie G. Oxymatrine inhibits development of morphine-induced tolerance associated with decreased expression of P-glycoprotein in rats. Integr Cancer Ther. 2010;9:213–8.CrossRefPubMed

72.

Nakagawa T, Ozawa T, Shige K, Yamamoto R, Minami M. Inhibition of morphine tolerance and dependence by MS-153, a glutamate transporter activator. Eur J Pharmacol. 2001;419:39–45.CrossRefPubMed

73.

Chaves C, Gomez-Zepeda D, Auvity S, Menet M-C, Crete D, Labat L, et al. Effect of subchronic intravenous morphine infusion and naloxone-precipitated morphine withdrawal on P-gp and Bcrp at the rat blood–brain barrier. J Pharm Sci. 2015;105:350–8.CrossRef

74.

Kahan M, Srivastava A, Wilson L, Gourlay D, Midmer D. Misuse of and dependence on opioids: study of chronic pain patients. Can Fam Physician. 2006;52(9):1081–7.PubMedPubMedCentral

75.

Gupta A, Christo PJ. Opioid abuse and dependence. J Nurse Pract. 2009;5:132–4.CrossRef

76.

Author. Substance-related and addictive disorders. In: Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013.

77.

Sonne S, Brady K. Substance abuse and bipolar comorbidity. Psychiatr Clin N Am. 1999;22:609–27.CrossRef

78.

Martins SS, Keyes KM, Storr CL, Zhu H, Chilcoat HD. Pathways between nonmedical opioid use/dependence and psychiatric disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Drug Alcohol Depend. 2009;103:16–24.CrossRefPubMedPubMedCentral

79.

Maremmani I, Giovanni A, Maremmani I, Rugani F, Rovai L, Pacini M, et al. Clinical presentations of substance abuse in bipolar heroin addicts at time of treatment entry. Ann Gen Psychiatry. 2012;11:1–7. https://doi.org/10.1186/1744-859X-11-23.CrossRef

80.

Executive Office of Health and Humand Serivices. Recovery Support. http://www.mass.gov. 2017. http://www.mass.gov/eohhs/gov/departments/dph/programs/substance-abuse/recovery-support.html. Accessed 1 Jan 2017.

81.

Birnbaum HG, White AG, Schiller M, Waldman T, Cleveland JJM, Setnik B, et al. Societal costs of opioid abuse, dependence and misuse in the United States. Value Health. 2010;13:A111. https://doi.org/10.1016/S1098-3015(10)72532-8.CrossRef

82.

Kanouse AB, Compton P. The epidemic of prescription opioid abuse, the subsequent rising prevalence of heroin use, and the federal response. J Pain Palliat Care Pharmacother. 2015;29:102–14. https://doi.org/10.3109/15360288.2015.1037521.CrossRefPubMed

83.

Shei A, Rice JB, Kirson NY, Bodnar K, Birnbaum HG, Holly P, et al. Sources of prescription opioids among diagnosed opioid abusers. Curr Med Res Opin. 2015;31:779–84. https://doi.org/10.1185/03007995.2015.1016607.CrossRefPubMed

84.

McDonald DC, Carlson KE. Estimating the prevalence of opioid diversion by “doctor shoppers” in the United States. PLoS ONE. 2013;8:e69241.CrossRefPubMedPubMedCentral

85.

Han H, Kass PH, Wilsey BL, Li C-S. Increasing trends in Schedule II opioid use and doctor shopping during 1999–2007 in California. Pharmacoepidemiol Drug Saf. 2014;23:26–35.CrossRefPubMed

86.

Aldridge J, Decary-Hetu D. Hidden wholesale: the drug diffusing capacity of online drug cryptomarkets. Int J Drug Policy. 2016;35:7–15.CrossRefPubMed

87.

Lange A, Lasser KE, Xuan Z, Khalid L, Beers D, Heymann OD, et al. Variability in opioid prescription monitoring and evidence of aberrant medication taking behaviors in urban safety-net clinics. Pain. 2015;156:335–40.CrossRefPubMedPubMedCentral

88.

Katz N, Panas L, Kim M, Audet A, Bilansky A, Eadie J, et al. Usefulness of prescription monitoring programs for surveillance—analysis of Schedule II opioid prescription data in Massachusetts, 1996–2006. Pharmacoepidemiol Drug Saf. 2010;19:115–23.CrossRefPubMed

89.

Lembke A. Why doctors prescribe opioids to known opioid abusers. N Engl J Med. 2012;367:1580–1.CrossRefPubMed

90.

Wilson HD, Dansie EJ, Kim MS, Moskovitz BL, Chow W, Turk DC, et al. Clinicians’ attitudes and beliefs about opioids survey (CAOS): instrument development and results of a national physician survey. J Pain. 2013;14:613–27. https://doi.org/10.1016/j.jpain.2013.01.769.CrossRefPubMed

91.

Jones CM, Lurie PG, Throckmorton DC. Effect of US drug enforcement administration’s rescheduling of hydrocodone combination analgesic products on opioid analgesic prescribing. J Am Med Assoc Intern Med. 2017;176:399–402.

92.

Kertesz S. Turning the tide or riptide? The changing opioid epidemic. Subst Abus. 2017;38:3–8.CrossRefPubMed

93.

Center for Behavioral Health Statistics and Quality. Behavioral health trends in the United States: results from the 2014 national survey on drug use and health. 2015. http://www.samhsa.gov/data/sites/default/files/NSDUH-FRR1-2014/NSDUH-FRR1-2014.pdf%5Cn, http://www.samhsa.gov/data/. Accessed 23 Dec 2016.

94.

Cicero TJ, Ellis MS, Harney J. Shifting patterns of prescription opioid and heroin abuse in the United States. N Engl J Med. 2015;373:1789–90.CrossRefPubMed

95.

The Office of the President of the United Sates. National drug control strategy. 2015. https://www.whitehouse.gov//sites/default/files/ondcp/policy-and-research/2015_national_drug_control_strategy_0.pdf. Accessed 23 Dec 2016.

96.

Spahn V, Massaly N, Temp J, Durmaz V, Sabri P, Reidelbach M, et al. A nontoxic pain killer designed by modeling of pathological receptor conformations. Science (80 −). 2017;355:966–9.CrossRef

97.

Kieffer BL, Gavériaux-ruff C. Exploring the opioid system by gene knockout. Prog Neurobiol. 2002;66:285–306.CrossRefPubMed

98.

Oeltjenbruns J, Schäfer M. Peripheral opioid analgesia: clinical applications. Anesth Tech Pain Manag. 2005;9:36–44.

99.

Arti H, Mehdinasab SA. The comparison effects of intra-articular injection of different opioids on postoperative pain relieve after arthroscopic anterior cruciate ligament reconstruction: a randomized clinical trial study. J Res Med Sci. 2011;16:1176–82.PubMedPubMedCentral

100.

Reuben SS, Sklar J. Current concepts review pain management in patients who undergo outpatient arthroscopic surgery of the knee. J Bone Jt Surg. 2000;82:1754–66.CrossRef

101.

Ding H, Czoty PW, Kiguchi N, Cami-kobeci G, Sukhtankar DD, Nader MA. A novel orvinol analog, BU08028, as a safe opioid analgesic without abuse liability in primates. Proc Natl Acad Sci USA. 2016;113:5511–8.CrossRef

102.

Emery EC, Luiz AP, Wood JN. Nav1.7 and other voltage-gated sodium channels as drug targets for pain relief. Expert Opin Ther Targets. 2016;20:975–83. https://doi.org/10.1517/14728222.2016.1162295.CrossRefPubMedPubMedCentral

103.

Hill KP, Palastro MD, Johnson B, Ditre JW. Cannabis and pain: a clinical review. Cannabis Cannabinoid Res. 2017;2:96–104.CrossRefPubMedPubMedCentral

104.

Ong CKS, Seymour RA, Lirk P, Merry AF. Combining paracetamol (acetaminophen) with nonsteroidal antiinflammatory drugs: a qualitative systematic review of analgesic efficacy for acute postoperative pain. Anesth Analg. 2010;110:1170–9.PubMed

105.

Hayden JA, Van Tulder MW, Tomlinson G. Systematic review: strategies for using exercise therapy to improve outcomes in chronic low back pain. Ann Intern Med. 2005;142:776–85.CrossRefPubMed

106.

Ibrahim MM, Patwardhan A, Gilbraith KB, Moutal A, Yang X, Chew LA. Long-lasting antinociceptive effects of green light in acute and chronic pain in rats. Pain. 2017;158:347–60.CrossRefPubMed

Title: The opioid epidemic: a central role for the blood brain barrier in opioid analgesia and abuse
Authors: Charles P. Schaefer
Margaret E. Tome
Thomas P. Davis
Publication date: 01-12-2017
Publisher: BioMed Central
Published in: Fluids and Barriers of the CNS / Issue 1/2017
Electronic ISSN: 2045-8118
DOI: https://doi.org/10.1186/s12987-017-0080-3

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

The opioid epidemic: a central role for the blood brain barrier in opioid analgesia and abuse

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2017

Effect of shear stress on iPSC-derived human brain microvascular endothelial cells (dhBMECs)

Is posture-related craniospinal compliance shift caused by jugular vein collapse? A theoretical analysis

Erratum to: The Wisconsin Hydrocephalus Survey: shunt-dependent hydrocephalus management style among members of the American Society of Pediatric Neurosurgeons

Do patients with schizophreniform and bipolar disorders show an intrathecal, polyspecific, antiviral immune response? A pilot study

Profiling of metalloprotease activities in cerebrospinal fluids of patients with neoplastic meningitis

Human jugular vein collapse in the upright posture: implications for postural intracranial pressure regulation